NCT04555486COMPLETEDanonymous

A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3

Sponsor

Source record

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Indication / condition

AI-normalized

Primary Hyperoxaluria Type 3

Intervention

Source record

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Source & freshness

Source record

NCT ID

NCT04555486

Original source

ClinicalTrials.gov

Source last updated

Sep 19, 2024

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT04555486

Title

A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Status

COMPLETED

Phase

PHASE1

Condition raw

Primary Hyperoxaluria Type 3

Condition normalized

Primary Hyperoxaluria Type 3

Modality raw

small molecule

Modality normalized

small molecule

Target raw

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Target normalized

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Interventions

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Public preview

Source record

The DCR-PHXC-104 study is designed to assess the safety, tolerability, and pharmacological parameters of a single dose of DCR-PHXC in Primary Hyperoxaluria Type 3 (PH3). Participants should have had at least one stone event within 12 months of screening and intact renal function.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1 Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of DCR-PHXC in Patients With Primary Hyperoxaluria Type 3

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04555486

Status

COMPLETED

Phase

PHASE1

Sponsor

Dicerna Pharmaceuticals, Inc., a Novo Nordisk company

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedSep 19, 2024

Internal syncJun 11, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04555486

Indication

Primary Hyperoxaluria Type 3

Modality

small molecule

Target

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Intervention

DCR-PHXC, Sterile Normal Saline (0.9% NaCl)

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.